The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • PolyNovo (PNV) has signed deal with group purchasing organisation Premier for the supply of NovoSorb BTM
  • NovoSorb BTM is a dermal scaffold that helps regenerate skin lost through extensive surgery or burns
  • The agreement between PolyNovo and Premier allows member hospitals access to BTM at special pricing and terms negotiated with PolyNovo
  • PolyNovo’s sales team will now be able to enter hospitals that were previously restricted and will have a streamlined procurement process to facilitate faster NovoSorb BTM adoption
  • PolyNovo shares are up 2.79 per cent, trading at $2.95

PolyNovo (PNV) has signed deal with group purchasing organisation Premier for the supply of NovoSorb BTM.

NovoSorb BTM is a dermal scaffold that helps regenerate skin lost through extensive surgery or burns.

The agreement between PolyNovo and the group purchasing organisation (GPO) allows Premier member hospitals access to BTM at the special pricing and terms negotiated with PolyNovo.

The program ensures that its member hospitals have timely access to products that can drive high-quality, cost-effective care.

Premier currently services around 4100 health facilities and hospital members, including over 2000 acute care hospitals with 100 trauma centres and 63 children’s hospitals.

From April 1, PolyNovo will have access to these hospitals and Premier’s regional representatives, responsible for introducing new technology to members to improve utilisation and care efficiencies.

PolyNovo’s marketing team and consultants will be providing the Premier team with training, materials and support to enable them to facilitate the uptake of NovoSorb BTM amongst their members.

“This signing with Premier, the second largest GPO in the U.S., is a major milestone,” said Managing Director of PolyNovo, Paul Brennan.

“These GPO agreements put our disruptive BTM on a much larger list of hospitals than our sales team can get around in the short term. We will continue expanding our sales team into new markets to support hospitals and surgeons but now also to match the geographical footprint of the GPOs”.

PolyNovo shares are up 2.79 per cent, trading at $2.95 at 2:55 pm AEDT.  

PNV by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…